Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled, Single-center Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin as Add-on to Intravenous Insulin-infusion in Adolescents and Adults With Type 1 Diabetes

NCT02325206 is registered in ClinicalTrials.gov with Kinderkrankenhaus auf der Bult as lead sponsor.

NCT NCT02325206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02325206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled, Single-center Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin as Add-on to Intravenous Insulin-infusion in Adolescents and Adults With Type 1 Diabetes
Lead sponsor
Kinderkrankenhaus auf der Bult
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2014
Completion date
December 31, 2015
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes